Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (513)	2/25/1999 9:05:00 AM
From: BRAVEHEART	Read Replies (1) \| Respond to of 4474

Just Out, biz.yahoo.com ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA - news) today announced the issuance of the fourth in a series of patents covering pharmaceutical regulation of fundamental cellular processes through protein dimerization. The claims in the ARIAD patent (U.S. Patent No. 5,871,753, issued on February 16, 1999) cover Dimerizer Drugs(TM) that bind to certain immunophilin or cyclophilin proteins. Such drugs are useful in regulating biological activity of genetically engineered cells. This patent enhances ARIAD's proprietary position for the commercial development of products based on the ARIAD Regulated Gene Expression Technology (ARGENT(TM)) system. ARIAD's recent in vivo studies and its collaboration with University of Pennsylvania investigator, Dr. James Wilson, were featured in a lead article in the Science Times section of the February 23, 1999 issue of the New York Times (''Gene Therapy Passes Important Test, in Monkeys'' by Nicholas Wade). Jeffrey